fluconazole has been researched along with Graft vs Host Disease in 20 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported." | 9.16 | Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. ( Langston, AA; O'Sullivan, AK; Pandya, A; Papadopoulos, G; Perfect, JR; Thompson, D; Weinstein, MC, 2012) |
| "The objective of this study was to evaluate the cost-effectiveness of posaconazole versus fluconazole for the prevention of invasive fungal infections (IFI) in graft-versus-host disease (GVHD) patients in the Netherlands." | 9.14 | Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. ( Jansen, JP; Janssen, JJ; Lugtenburg, E; O'Sullivan, AK; Span, LF; Stam, WB, 2010) |
| "In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy." | 9.12 | Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007) |
| "To evaluate the cost-effectiveness of solid oral tablets of posaconazole versus fluconazole capsules for the prophylaxis of IFDs in allogeneic HSCT recipients with graft-versus-host disease (GVHD) in Spain." | 7.88 | Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2018) |
| " CsA was immediately stopped, and tacrolimus for prevention of graft-versus-host disease (GVHD) was started on day 2." | 7.71 | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. ( Asaka, M; Chiba, K; Hashino, S; Izumiyama, K; Suzuki, S; Takahata, M, 2001) |
| "Fluconazole prophylaxis was defined by a minimum of 5 prophylactic doses." | 6.69 | The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. ( Bowden, RA; Hackman, RC; Leisenring, W; McDonald, GB; Myerson, D; Sale, GE; Shulman, HM; van Burik, JH, 1998) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 5.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported." | 5.16 | Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. ( Langston, AA; O'Sullivan, AK; Pandya, A; Papadopoulos, G; Perfect, JR; Thompson, D; Weinstein, MC, 2012) |
| "The objective of this study was to evaluate the cost-effectiveness of posaconazole versus fluconazole for the prevention of invasive fungal infections (IFI) in graft-versus-host disease (GVHD) patients in the Netherlands." | 5.14 | Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. ( Jansen, JP; Janssen, JJ; Lugtenburg, E; O'Sullivan, AK; Span, LF; Stam, WB, 2010) |
| "In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy." | 5.12 | Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007) |
| "To evaluate the cost-effectiveness of solid oral tablets of posaconazole versus fluconazole capsules for the prophylaxis of IFDs in allogeneic HSCT recipients with graft-versus-host disease (GVHD) in Spain." | 3.88 | Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2018) |
| " infusion of tacrolimus for graft-versus-host disease prophylaxis." | 3.79 | Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ( Bunin, N; Goyal, RK; Grupp, SA; Han, K; Mada, SR; Pulsipher, MA; Venkataramanan, R; Wall, DA, 2013) |
| " CsA was immediately stopped, and tacrolimus for prevention of graft-versus-host disease (GVHD) was started on day 2." | 3.71 | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. ( Asaka, M; Chiba, K; Hashino, S; Izumiyama, K; Suzuki, S; Takahata, M, 2001) |
| "Fluconazole prophylaxis was defined by a minimum of 5 prophylactic doses." | 2.69 | The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. ( Bowden, RA; Hackman, RC; Leisenring, W; McDonald, GB; Myerson, D; Sale, GE; Shulman, HM; van Burik, JH, 1998) |
| " However, the ideal dosage of fluconazole has never been tested." | 1.48 | A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. ( Bramanti, S; Carlo-Stella, C; Casari, E; Castagna, L; Crocchiolo, R; De Philippis, C; Mariotti, J; Morabito, L; Pocaterra, D; Rimondo, A; Santoro, A; Sarina, B; Tordato, F, 2018) |
| "Posaconazole was associated with fewer IFIs (5." | 1.36 | Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. ( Carreras, E; Casado, MA; de la Cámara, R; Grau, S; Jarque, I; Sabater, FJ; Sanz, MA, 2010) |
| "Fluconazole prophylaxis was not used during the study period." | 1.32 | Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. ( Anttila, VJ; Jantunen, E; Juvonen, E; Nihtinen, A; Parkkali, T; Ruutu, T; Volin, L, 2004) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 1.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "Oral fluconazole treatment thus did not eradicate the fungal infection, but achieved significant control of the meningitis on an outpatient basis." | 1.28 | Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient. ( Bastianello, S; Girmenia, C; Iori, AP; Martino, P; Meloni, G; Micozzi, A; Venditti, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, TE | 1 |
| Stansfield, L | 1 |
| Kumar, P | 1 |
| Worthy, T | 1 |
| Tian, X | 1 |
| Childs, RW | 1 |
| Nwaroh, E | 1 |
| Jupp, J | 1 |
| Jadusingh, E | 1 |
| Guilcher, G | 1 |
| Grau, S | 2 |
| Cámara, R | 1 |
| Jurado, M | 1 |
| Sanz, J | 1 |
| Aragón, B | 1 |
| Gozalbo, I | 1 |
| Sarina, B | 1 |
| Mariotti, J | 1 |
| Bramanti, S | 1 |
| Morabito, L | 1 |
| Crocchiolo, R | 1 |
| Rimondo, A | 1 |
| Tordato, F | 1 |
| Pocaterra, D | 1 |
| Casari, E | 1 |
| De Philippis, C | 1 |
| Carlo-Stella, C | 1 |
| Santoro, A | 1 |
| Castagna, L | 1 |
| Manning, MA | 1 |
| Kuo, PH | 1 |
| Yeager, AM | 1 |
| Kubisiak-Rzepczyk, H | 1 |
| Gil, L | 1 |
| Zawirska, A | 1 |
| Kubisiak-Michalska, A | 1 |
| Mol, A | 1 |
| Reich, A | 1 |
| Komarnicki, M | 1 |
| Adamski, Z | 1 |
| Gergis, U | 1 |
| Markey, K | 1 |
| Greene, J | 1 |
| Kharfan-Dabaja, M | 1 |
| Field, T | 1 |
| Wetzstein, G | 1 |
| Schell, MJ | 1 |
| Huang, Y | 1 |
| Anasetti, C | 1 |
| Perkins, J | 1 |
| de la Cámara, R | 1 |
| Jarque, I | 1 |
| Sanz, MA | 1 |
| Casado, MA | 1 |
| Sabater, FJ | 1 |
| Carreras, E | 1 |
| Jansen, JP | 1 |
| O'Sullivan, AK | 2 |
| Lugtenburg, E | 1 |
| Span, LF | 1 |
| Janssen, JJ | 1 |
| Stam, WB | 1 |
| Weinstein, MC | 1 |
| Pandya, A | 1 |
| Thompson, D | 1 |
| Langston, AA | 1 |
| Perfect, JR | 1 |
| Papadopoulos, G | 1 |
| Goyal, RK | 1 |
| Han, K | 1 |
| Wall, DA | 1 |
| Pulsipher, MA | 1 |
| Bunin, N | 1 |
| Grupp, SA | 1 |
| Mada, SR | 1 |
| Venkataramanan, R | 1 |
| Marr, KA | 1 |
| Crippa, F | 1 |
| Leisenring, W | 2 |
| Hoyle, M | 1 |
| Boeckh, M | 1 |
| Balajee, SA | 1 |
| Nichols, WG | 1 |
| Musher, B | 1 |
| Corey, L | 1 |
| Jantunen, E | 1 |
| Nihtinen, A | 1 |
| Volin, L | 1 |
| Juvonen, E | 1 |
| Parkkali, T | 1 |
| Ruutu, T | 1 |
| Anttila, VJ | 1 |
| Ullmann, AJ | 1 |
| Lipton, JH | 1 |
| Vesole, DH | 1 |
| Chandrasekar, P | 1 |
| Langston, A | 1 |
| Tarantolo, SR | 1 |
| Greinix, H | 1 |
| Morais de Azevedo, W | 1 |
| Reddy, V | 1 |
| Boparai, N | 1 |
| Pedicone, L | 1 |
| Patino, H | 1 |
| Durrant, S | 1 |
| De Pauw, BE | 1 |
| Donnelly, JP | 1 |
| Krause, DS | 1 |
| van Burik, JH | 1 |
| Myerson, D | 1 |
| Hackman, RC | 1 |
| Shulman, HM | 1 |
| Sale, GE | 1 |
| Bowden, RA | 1 |
| McDonald, GB | 1 |
| Takahata, M | 1 |
| Hashino, S | 1 |
| Izumiyama, K | 1 |
| Chiba, K | 1 |
| Suzuki, S | 1 |
| Asaka, M | 1 |
| Safdar, A | 1 |
| van Rhee, F | 1 |
| Henslee-Downey, JP | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Girmenia, C | 1 |
| Micozzi, A | 1 |
| Venditti, M | 1 |
| Meloni, G | 1 |
| Iori, AP | 1 |
| Bastianello, S | 1 |
| Martino, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation[NCT01160952] | Phase 2 | 120 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| [NCT00034645] | Phase 3 | 600 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147] | 300 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for fluconazole and Graft vs Host Disease
| Article | Year |
|---|---|
Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
Topics: Adult; Double-Blind Method; Female; Fluconazole; Graft vs Host Disease; Humans; Male; Models, Econom | 2010 |
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
Topics: Antifungal Agents; Cost-Benefit Analysis; Fluconazole; Graft vs Host Disease; Humans; Itraconazole; | 2012 |
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.
Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host | 2004 |
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.
Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host | 2004 |
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.
Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host | 2004 |
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.
Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host | 2004 |
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole; | 2007 |
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole; | 2007 |
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole; | 2007 |
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole; | 2007 |
The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.
Topics: Adolescent; Adult; Antifungal Agents; Autopsy; Bone Marrow Transplantation; Candidiasis; Cohort Stud | 1998 |
15 other studies available for fluconazole and Graft vs Host Disease
| Article | Year |
|---|---|
A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD.
Topics: Adult; Budesonide; Cross-Over Studies; Fluconazole; Graft vs Host Disease; Hematopoietic Stem Cell T | 2020 |
Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients.
Topics: Adolescent; Alberta; Bone Marrow Transplantation; Child; Disease Management; Drug Interactions; Fema | 2018 |
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Topics: Antifungal Agents; Cost-Benefit Analysis; Female; Fluconazole; Graft vs Host Disease; Hematopoietic | 2018 |
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antifungal Agents; Dose-Response Relationship, Drug | 2018 |
Disseminated coccidioidomycosis masquerading as recurrent lymphoma.
Topics: Antifungal Agents; Coccidioides; Coccidioidomycosis; Diagnosis, Differential; Female; Fluconazole; G | 2018 |
Scedosporium prolificans fungaemia in a patient with acute lymphoblastic leukaemia.
Topics: Allografts; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.
Topics: Adult; Antifungal Agents; Chemoprevention; Female; Fluconazole; Glucocorticoids; Graft vs Host Disea | 2010 |
Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
Topics: Antifungal Agents; Cost-Benefit Analysis; Fluconazole; Graft vs Host Disease; Hematopoietic Stem Cel | 2010 |
Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.
Topics: Adolescent; Antifungal Agents; Area Under Curve; Bone Marrow Transplantation; Child; Child, Preschoo | 2013 |
Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Female; Fluconazole; Fungemia; Graft vs Hos | 2004 |
Prophylaxis and aspergillosis--has the principle been proven?
Topics: Antifungal Agents; Aspergillosis; Fluconazole; Graft vs Host Disease; Humans; Itraconazole; Mycoses; | 2007 |
Posaconazole prophylaxis in hematologic cancer.
Topics: Antifungal Agents; Bilirubin; Chemical and Drug Induced Liver Injury; Fluconazole; Graft vs Host Dis | 2007 |
Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus.
Topics: Adult; Anemia, Aplastic; Anticonvulsants; Blood-Brain Barrier; Bone Marrow Transplantation; Brain Di | 2001 |
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis; | 2001 |
Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient.
Topics: Adolescent; Bone Marrow Transplantation; Female; Fluconazole; Graft vs Host Disease; Humans; Meningi | 1991 |